Our mission
We have created a new ex vivo skin testing platform that we believe is the most effective way to maintain skin in culture. While scientifically we have come a long way in developing new types of 3D skin models and systems that aim to mimic human skin, fundamentally, there are still limitations. Many in vitro skin tests are only 60-80% accurate and often require a number of combined tests to increase accuracy above 95%. We strive to resolve the limitations of current regulatory standards.
What we do
Keratify aims to change ex vivo human skin testing practices globally to one that is quicker, more efficient and more accurate than existing methods.
Contact us to discuss how our technology can accelerate your skin care R&D. Housed in one of the largest dermatology research laboratories in Europe, our capabilities can address even the most complex dermatology questions.
Who we are
Keratify was founded by Dr Ros Hannen in 2018, with over 13 years experience in dermatology research, she truly understands what is needed to advance skin testing. Keratify is supported with a great team, including Dr Rafa Castrejon-Pita, an expert physicist; Dr Karl Lawrence, with a PhD in UV skin biology. Our advisors are among the best in the world, including Rani Saad and Prof Mike Philpott, with extensive experience in cosmetics, medical aesthetics, engineering and business development.
How we got here
Our in vitro human skin testing technology has been accelerated through winning a number of prestigious awards. In June 2018 we joined cohort 1 of the MedTech SuperConnector scheme funded by Research England. We then won a Life Sciences Initiative award in February 2019 from Queen Mary University of London. Keratify is now the recipient of an Innovate UK Smart Grant, considered one of the most competitive funding awards.
